CENTURY THERAPEUTICS INC (IPSC)

US15673T1007 - Common Stock

1.07  +0.01 (+0.94%)

After market: 1.0719 +0 (+0.18%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
5.2M2.235M
-57.02%
7.388M
230.56%
9.741M
31.85%
4.08M
-58.12%
72.012M
1,665.00%
117.93M
63.76%
300.9M
155.15%
552.84M
83.73%
985.32M
78.23%
EBITDA
YoY % growth
-91.13M
-90.73%
-115.39M
-26.62%
-112.137M
2.82%
-128.653M
-14.73%
-143.942M
-11.88%
N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-94.88M
-92.92%
-123.83M
-30.51%
-125.181M
-1.09%
-144.579M
-15.50%
-171.515M
-18.63%
-186.079M
-8.49%
-227.46M
-22.24%
-186.66M
17.94%
46.92M
125.14%
271.32M
478.26%
650.76M
139.85%
Operating Margin
N/A-2,381.35%-5,600.94%-1,956.94%-1,760.75%-4,560.75%-315.86%-158.28%15.59%49.08%66.05%
EPS
YoY % growth
N/A-2.28
30.47%
-2.29
-0.44%
-1.66
27.64%
-1.35
18.55%
-1.95
-44.34%
-2.01
-3.14%
-1.31
35.03%
0.09
107.03%
1.53
1,566.67%
N/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-0.43
33.49%
-0.45
0.72%
-0.44
-17.03%
-0.46
-23.12%
-0.48
-10.61%
-0.48
-7.31%
-0.49
-10.09%
-0.49
-7.48%
-0.50
-4.52%
Revenue
Q2Q % growth
2.249M
739.18%
2.749M
221.52%
2.888M
274.58%
2.908M
267.64%
2.848M
26.63%
1.02M
-62.90%
1.02M
-64.68%
1.02M
-64.92%
1.02M
-64.19%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-41.054M
-34.09%
-39.882M
-27.38%
-42.16M
-21.31%
-43.418M
-24.80%
-45.526M
-10.89%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.37
32.73%
-0.460.0919.03%
Q2 2024
Q2Q % growth
-0.38
32.14%
-0.470.0919.26%
Q1 2024
Q2Q % growth
-0.45
15.09%
-0.510.0612.12%
Q4 2023
Q2Q % growth
-0.65
-18.18%
-0.57-0.08-14.97%
Q3 2023
Q2Q % growth
-0.55
-3.77%
-0.52-0.03-5.20%
Q2 2023
Q2Q % growth
-0.56
-3.70%
-0.560.00-0.88%
Q1 2023
Q2Q % growth
-0.53
19.70%
-0.530.000.73%
Q4 2022
Q2Q % growth
-0.55
-129.17%
-0.600.059.01%
Q3 2022
Q2Q % growth
-0.53
-10.42%
-0.610.0812.65%
Q2 2022
Q2Q % growth
-0.54
72.02%
-0.53-0.01-2.60%
Q1 2022
Q2Q % growth
-0.66 -0.46-0.20-43.00%
Q4 2021
Q2Q % growth
-0.24 -0.490.2550.72%
Q3 2021
Q2Q % growth
-0.48 -0.41-0.07-17.65%
Q2 2021
Q2Q % growth
-1.93 -0.43-1.50-354.11%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
791K
434.46%
2.064M-1.273M-61.68%
Q2 2024
Q2Q % growth
771K
678.79%
1.97M-1.199M-60.86%
Q1 2024
Q2Q % growth
855K
-50.29%
1.287M-432K-33.57%
Q4 2023
Q2Q % growth
268K
-48.46%
1.874M-1.606M-85.70%
Q3 2023
Q2Q % growth
148K
-93.33%
1.185M-1.037M-87.51%
Q2 2023
Q2Q % growth
99K
-92.93%
1.164M-1.065M-91.49%
Q1 2023
Q2Q % growth
1.72M
62.26%
1.336M384K28.74%
Q4 2022
Q2Q % growth
520K 2.009M-1.489M-74.12%
Q3 2022
Q2Q % growth
2.22M 1.151M1.069M92.88%
Q2 2022
Q2Q % growth
1.4M 975.559K424.441K43.51%
Q1 2022
Q2Q % growth
1.06M 5.1M-4.04M-79.22%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 12.9% 0% 8.49%
Revenue0% -1.4% -0.01% -0.85%